Assuntos
COVID-19/patologia , Dermatologia/estatística & dados numéricos , Serviços Médicos de Emergência/estatística & dados numéricos , Encaminhamento e Consulta/estatística & dados numéricos , COVID-19/diagnóstico , COVID-19/epidemiologia , COVID-19/virologia , Dermatologia/normas , Serviços Médicos de Emergência/tendências , Humanos , Encaminhamento e Consulta/tendências , Estudos Retrospectivos , SARS-CoV-2/genética , Estações do Ano , Espanha/epidemiologia , Centros de Atenção Terciária/organização & administração , Fatores de TempoRESUMO
BACKGROUND: Recent studies suggest that cutaneous melanoma mortality rates in Spain are stabilizing and even decreasing in younger cohorts. OBJECTIVES: To analyse mortality rates of melanoma from the last 40 years, focusing on changes related with the development of new therapeutic approaches. METHODS: Death records and mid-year population data were collected from the National Statistics Institute. By using the direct method, age-standardized mortality rates were calculated for overall population and for each sex and age group. Significant changes in mortality trends were identified by Joinpoint regressions. The independent effects of age, period and cohort (APC) and potential years of life lost (PYLL) due to melanoma were also analysed. RESULTS: Age-standardized melanoma mortality rates rose in Spain from 0.78 to 2.13 deaths per 100 000 from the first to the last quinquennium of the study (1979-1983 to 2014-2018) for the overall population. After a marked increase until 1995, mortality rates levelled off. Following this stabilization, from 2015 to 2018 there was a decrease in mortality rates for the overall population (average annual per cent change (AAPC): -4.3, not significant), more accused in males over 64 years old (yo). A period effect was observed from the beginning of 21st century, with mortality rates dropping to date. CONCLUSIONS: There is a decrease in melanoma mortality rates from 2015 in all age groups that confirms previous trends in mortality in younger cohorts. Improvement in diagnosis and development of new therapies for advanced melanoma may have a crucial role in this event. Close monitoring of melanoma mortality rates is necessary to confirm these trends.
Assuntos
Melanoma , Neoplasias Cutâneas , Estudos de Coortes , Humanos , Imunoterapia , Masculino , Melanoma/terapia , Pessoa de Meia-Idade , Neoplasias Cutâneas/terapia , Espanha/epidemiologiaRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Queilite/terapia , Resultado do Tratamento , Carcinoma de Células Escamosas/terapia , Neoplasias Labiais/etiologia , Queilite/patologia , Sintase do Porfobilinogênio/uso terapêutico , Lábio/efeitos dos fármacos , Lábio/patologia , Protetores Solares/uso terapêutico , Medição da Dor/métodos , Carcinoma de Células Escamosas/etiologiaRESUMO
No disponible
